Trials / Completed
CompletedNCT03345043
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VAL-339851 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VAL-339851 | Escalating dose levels |
| OTHER | Placebo | Saline |
Timeline
- Start date
- 2016-05-11
- Primary completion
- 2018-08-13
- Completion
- 2018-08-13
- First posted
- 2017-11-17
- Last updated
- 2021-01-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03345043. Inclusion in this directory is not an endorsement.